Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12123823 | 0.82 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL15223529 | 0.82 | ATM (0.36) | NPC1RAB9ASMN1; SMN2ATMCA1 | |
| SCHEMBL21447009 | 0.82 | ATM (0.40) | NPC1RAB9ASMN1; SMN2ATMLMNA | |
| SCHEMBL27335208 | 0.82 | CA1 (0.39) | NPC1RAB9ASMN1; SMN2ATMCA1 | |
| SCHEMBL12049034 | 0.80 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2LMNAABCB1 | |
| SCHEMBL23047877 | 0.79 | MAOB (0.34) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| SCHEMBL22064761 | 0.79 | ATM (0.41) | NPC1RAB9ASMN1; SMN2ATMLMNA | |
| SCHEMBL22788212 | 0.79 | ATM (0.37) | NPC1RAB9ASMN1; SMN2ATMCA1 | |
| SCHEMBL22052108 | 0.79 | MAOB (0.34) | NPC1RAB9ASMN1; SMN2LMNAMAOB | |
| SCHEMBL22065385 | 0.77 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2024115546-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024026500-A2 | INHIBITORS OF PDE11A4 AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023177356-A2 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023164237-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164233-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230058677-A1 | POLYCYCLIC PYRIDOPYRAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| WO-2009155448-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | LIGAND PHARMACEUTICALS INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004021987-A2 | TREATMENT OF RHEUMATOID ARTHRITIS BY INHIBITION OF PDE4 | MERCK & CO., INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | NPC1 3/4885RAB9A 3451/4885SMN1; SMN2 4707/4885 |
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | NPC1 2990/4885RAB9A 1819/4885SMN1; SMN2 4587/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | NPC1 3/4885RAB9A 3451/4885SMN1; SMN2 4707/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | NPC1 410/4885RAB9A 2793/4885SMN1; SMN2 4823/4885 |
| US-11649224-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | NPC1 1746/4885RAB9A 2923/4885SMN1; SMN2 2182/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885RAB9A 2053/4885SMN1; SMN2 2486/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885RAB9A 876/4885SMN1; SMN2 2298/4885 |
| US-20230058677-A1 | POLYCYCLIC PYRIDOPYRAZINE DERIVATIVE | C5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | NPC1 2375/4885RAB9A 2779/4885SMN1; SMN2 4870/4885 |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | ERG28, CBR3, CBR1 | NPC1 210/4885RAB9A 1677/4885SMN1; SMN2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.